Hetero Expands in South Africa as

0

Years of Service

0

APIs

0

FDFs

0

Countries

0

State-of-the-art manufacturing facilities

0

Employees globally

Introduction to Hetero South Africa

Introduction to Hetero South Africa

Hetero’s business venture in South Africa began in 2008 with the filing of multiple dossiers with SAHPRA (South African Health Products Regulatory Authority), leading to the official commercialization of these products in 2016 with the establishment of Hetero Drugs South Africa (Pty) Ltd.

Between 2008 and 2016, over 100 high-quality dossiers were filed. These products are manufactured at USFDA, EU, and SAHPRA-approved facilities, ensuring compliance with global pharmaceutical standards.

Hetero launched its operations with a focus on ARV drugs in South Africa, expanded to include oncology medications in 2022, and further broadened its reach with Primary Care and Hospital divisions in 2024.

The South African team operates from Waterfall Corporate Campus in Midrand with a strong staff complement of 45 professionals, including field force and functional departments such as Regulatory Affairs, HR, Finance, and Supply Chain.

Milestones and Achievements:


Hetero South Africa entered the public healthcare sector in 2019 by securing a significant R2 billion ARV tender, marking a major milestone in its journey. In 2022, the company expanded its presence in the public sector by winning a R5 billion supply contract, enabling the distribution of over 1.3 million packs of medicines every month.



During the COVID-19 pandemic, Hetero played a crucial role by supplying 1 million packs of TLD (Tenofovir, Lamivudine, and Dolutegravir) over a span of five months in collaboration with the National Department of Health (NDoH) to manage ARV shortages. Additionally, Hetero ensured the emergency supply of over 20,000 packs of COVIFOR (Remdesivir) to hospitals across South Africa, providing critical support during the peak of the pandemic.

Milestones

Comprehensive Product Portfolio

As a global pharmaceutical company committed to affordable healthcare in South Africa, Hetero focuses on the development, manufacturing, and distribution of: Active Pharmaceutical Ingredients (APIs) &Finished Dosage Formulations (FDFs).

Anti retro virals (ARV)

Oncology

Primary Care drugs

Critical care & Hospital injectables

Our commitment to cost-effective and high-quality medicines ensures improved patient outcomes in both the public and private healthcare sectors across South Africa.

Flagship Products

Career Opportunities at Hetero South Africa

Are you looking to build a rewarding career in the pharmaceutical industry in South Africa? At Hetero Africa, we believe that innovation thrives in an environment of opportunity, collaboration, and purpose. As part of a global pharmaceutical leader, we are committed to nurturing talent, fostering growth, and empowering individuals to make a lasting impact on healthcare.

At Hetero, you will find:

  • A collaborative and inclusive workplace that values diverse perspectives and encourages teamwork across all functions.
  • Ongoing learning and development programs designed to help you upskill, stay current with industry trends, and grow professionally.
  • Clear career advancement pathways across departments such as Regulatory Affairs, Sales & Marketing, Medical Affairs, Supply Chain.
  • Opportunities to work with a globally recognised companies, contributing to large-scale health initiatives and impactful innovations.

Explore your potential and make a meaningful impact on public health by becoming a part of the Hetero South Africa family.



Join Us

Explore the current open positions. Connect with us on email: talent@hetero.com
to build a rewarding career at Hetero South Africa.

Map and Directions

We welcome you to visit our office or contact us by phone for any assistance.



Stay Connected

Stay connected with Hetero South Africa for the latest updates on career opportunities, product information, and more. We are committed to elevating healthcare standards and ensuring a healthier future for all.